Skip to main content

Market Overview

UBS Downgrades Auxilium Pharmaceuticals To Neutral

Share:

Analysts at UBS downgraded Auxilium Pharmaceuticals (NASDAQ: AUXL) from Buy to Neutral.

Auxilium Pharmaceuticals shares have jumped 64.74% over the past 52 weeks, while the S&P 500 index has surged 17.63% in the same period.

Auxilium Pharma's shares fell 3.98% to $29.88 in pre-market trading.

Latest Ratings for AUXL

DateFirmActionFromTo
Oct 2014MizuhoDowngradesBuyNeutral
Oct 2014MKM PartnersDowngradesBuyNeutral
Sep 2014RBC CapitalDowngradesOutperformSector Perform

View More Analyst Ratings for AUXL
View the Latest Analyst Ratings

 

Related Articles (AUXL)

View Comments and Join the Discussion!

Posted-In: UBSDowngrades Analyst Ratings

Latest Ratings

StockFirmActionPT
GIKColliers SecuritiesInitiates Coverage On14.0
SANWLake StreetInitiates Coverage On6.0
LILAMorgan StanleyDowngrades15.0
BEJP MorganUpgrades36.0
NEXACredit SuisseUpgrades11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com